# OnCo record duo-e (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/duo-e/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "duo-e", "NCT04269200" ;
  schema:name "DUO-E / GOG-3041 / ENGOT-EN10"@en ;
  schema:description "A third immunotherapy confirmed the benefit in dMMR disease and hinted that adding olaparib helps the mismatch-repair-proficient majority."@en ;
  schema:url <https://onco.cc/trials/duo-e/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04269200>, <https://ascopubs.org/doi/10.1200/JCO.23.02132> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2020-05-05" ;
  onco:cancers <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/endometrial-mmr-deficient/>, <https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/msi/> .